| Similar Articles |
|---|
 |
The Motley Fool
May 2, 2007
Brian Lawler |
Vanda Advancing The development-stage biotech releases first-quarter financial results. Investors, take note.   |
The Motley Fool
November 12, 2007
Brian Lawler |
Vanda Gets Set for a Busy 2008 Although it has no marketed products, Vanda Pharmaceuticals third-quarter reports set the stage for an exciting 2008. Investors. take note. |
The Motley Fool
August 1, 2007
Brian Lawler |
A Closer Look at Vanda Vanda Pharmaceuticals is a development stage drug maker worth keeping an eye on. Later this year Vanda plans to submit a New Drug Application to the FDA for its anti-psychotic medication, iloperidone. |
The Motley Fool
September 27, 2007
Brian Lawler |
A Step in a Winding Road for Vanda Vanda Pharmaceuticals has submitted a new drug application to the FDA for its lead drug, iloperidone, emphasizing a new approach to reduce safety issues. Investors, take note. |
The Motley Fool
December 7, 2006
Billy Fisher |
Breakout at Vanda Good news on the company's schizophrenia drug sends its shares skyrocketing. |
The Motley Fool
June 27, 2008
Brian Lawler |
Vanda's Drug Draws a Yawn Shares of Vanda Pharmaceuticals have fallen more than 20% recently, even though the company said that its phase 3 clinical trial met its primary goal. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
November 17, 2006
Billy Fisher |
Vanda Shareholders Sleeping Better The latest news on the company's insomnia drug boosts the stock. |
The Motley Fool
September 30, 2010
Brian Orelli |
Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers. |
The Motley Fool
July 21, 2011
Brian Orelli |
Keep an Eye on Biotech Partners' Earnings Novartis' earnings are important for small biotechs Momenta and Vanda. |
The Motley Fool
May 19, 2009
Brian Orelli |
Flip-Flopping: Not Just for Politicians Anymore The FDA's change is good for companies. |
The Motley Fool
May 18, 2009
Brian Orelli |
Is There Life After 600% Returns? Just because a drug company gets a massive increase in the stock price after a positive clinical trial or an FDA approval, that doesn't mean all the growth is completely factored into the stock price. |
The Motley Fool
December 12, 2006
Matt Koppenheffer |
The 5-Sigma Report A look at the stocks that saw serious volatility last week. Gallaher Group... Kyphon... Vanda Pharmaceuticals... Bank of New York... Pfizer... |
The Motley Fool
August 27, 2008
Brian Orelli |
Another FDA Setback for Johnson & Johnson The company has to wait for an approval of its extended-release schizophrenia drug. Investors, take note. |
The Motley Fool
November 26, 2007
Brian Lawler |
Glaxo Goes Holiday Shopping The pharmaceutical giant snaps up another acquisition, privately held Reliant Pharmaceuticals, for $1.65 billion in cash, one of the largest pharma deals of the year. |
The Motley Fool
December 22, 2009
Brian Orelli |
2009 Biotech Cheers and Jeers Lessons from biotech's 2009 surprises. Will 2010 be just as exciting? Considering that it's biotech, I'd have to say "yes." |
The Motley Fool
November 4, 2011
Brian Orelli |
You Should Have Seen These Biotech Failures Coming Micro cap biotechs are a value for a reason. |
